Skip to main content
ConductScienceScienceDex
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

1,301

datasets available to search

ShareScore release 0.9.0

Reset

Dataset results

1,301 results for “retrospective study”

Learn how ShareScore rates datasets ↗
zenodo12/100

Dataset related to article: "Nocturnal Hypoxemia Impacts Right Ventricle Diastolic Function in Obstructive Sleep Apnea: A Retrospective Observational Study"

<p>We provide the raw data used for the following article:</p> <ul> <li>Scotti C, Porta R, Olivares A, Comini L, Cinelli A, Scalvini S, Vitacca M.<br> <em>Nocturnal Hypoxemia Impacts Right Ventricle Diastolic Function in Obstructive Sleep Apnea: A Retrospective Observational Study.</em><br> &quot;J Clin Med.&quot; 2020 Jan 7;9(1):162. doi: 10.3390/jcm9010162. PMID: 31936097; PMCID: PMC7019852.</li> </ul> <p>&nbsp;</p> <p><strong>Abstract</strong><br> Obstructive sleep apnea (OSA), although a growing healthcare problem and documented risk factor for cardiovascular diseases, is still under-diagnosed in cardiac patients. To investigate the correlation between OSA and echocardiographic parameters of right ventricle diastolic (RVD) dysfunction, in particular trans-tricuspid E-wave deceleration time (EDT), we retrospectively analyzed data of 103 pure (comorbidity-free) OSA patients with comprehensive echocardiographic examination (ETT). Apnea/hypopnea index (AHI), oxygen desaturation index (ODI), mean nighttime oxyhemoglobin saturation (SpO2), time elapsed with SpO2&nbsp;&lt; 90% (T90) and mean peak desaturation of nocturnal events (Mdes, graded as mild, medium or severe) were compared with echocardiographic parameters. We found RVD dysfunction present in 58.3% of patients. Altered EDT correlated significantly with mean SpO2, T90, and Mdes (p &lt; 0.01, all). Nocturnal desaturators had a significantly worse EDT than non-desaturators (p = 0.027) and a higher risk of prolonged EDT (odds ratio, OR = 2.86). EDT differed significantly according to Mdes severity (p = 0.005) with a higher risk of prolonged EDT in medium/severe vs. mild Mdes (OR = 3.44). EDT detected the presence of RVD dysfunction in 58.3% of our pure OSA patients. It correlated poorly with AHI severity but strongly with nocturnal desaturation severity, independently of age. This ETT marker may be useful for deciding appropriate diagnostic and therapeutic strategies.</p>

restrictedSep 2021View details →
zenodo12/100

Dataset related to article "Real life long-term efficacy and safety of ixekizumab in moderate-to-severe psoriasis: A 192 weeks multicentric retrospective study-IL PSO (Italian landscape psoriasis)"

<p>This record contains raw data related to article &ldquo;Real life long-term efficacy and safety of ixekizumab in moderate-to-severe psoriasis: A 192 weeks multicentric retrospective study-IL PSO (Italian landscape psoriasis)&quot;</p> <p>&nbsp;</p> <p>Abstract:</p> <p>Psoriasis is one of the commonest inflammatory skin diseases determining a very high impact on patients&#39; quality of life and daily activities and relationships. Several biologic therapies have been approved through the years for the treatment of moderate-to-severe plaque psoriasis, and efficacy and safety profile have been analyzed in clinical trials. Ixekizumab is an immunoglobulin G subclass 4 monoclonal antibody that selectively targets and binds IL-17A with high specificity and affinity. Inhibiting IL-17A activity, ixekizumab reduces and turns down levels of inflammation, resulting in the clinical improvement of the disease. Long-term efficacy and safety profile of ixekizumab have been investigated and reported in the UNCOVER trials, but in literature there are only few studies based on real life experience. We present the efficacy and safety profile of ixekizumab in a cohort of 779 patients affected by moderate-to-severe plaque psoriasis and treated with ixekizumab in 11 Italian dermatology hospitals, with a follow-up of care until 192 weeks.</p>

restrictedNov 2022View details →
zenodo12/100

Dataset related to article "Real-life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52-week multicentre retrospective study-IL PSO (Italian landscape psoriasis) "

<p>This record contains raw data related to article &ldquo;Real-life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52-week multicentre retrospective study-IL PSO (Italian landscape psoriasis)&quot;</p> <p>Abstract</p> <p><strong>Background: </strong> Tildrakizumab is a humanized monoclonal antibody that binds selectively the p19 subunit of interleukin-23. It is approved for treatment of moderate-severe chronic plaque psoriasis.</p> <p><strong>Objectives: </strong> We conducted a 52-week retrospective study to assess the effectiveness and safety of tildrakizumab in a real-life setting.</p> <p><strong>Methods: </strong> Our retrospective study included 237 consecutive adults with moderate-to-severe plaque psoriasis, enrolled in 10 different Italian centres, treated with tildrakizumab up to Week 52. Patient characteristics, comorbidities, previous treatments and the PASI (Psoriasis Area and Severity Index) score at each visit (baseline, Week 16, Week 28 and Week 52) were retrieved from the electronic medical records. The percentages of patients achieving 75%, 90% and 100% (PASI 75, PASI 90 and PASI 100) improvement in PASI with respect to baseline PASI were registered.</p> <p><strong>Results: </strong> At Week 52, 90.91%, 73.55% and 58.68% of patients achieved a PASI reduction &ge;75% (PASI 75), PASI 90 and PASI 100, respectively. An absolute PASI &le; 2 was reached by 85.95% at Week 52. Compared with Phase 3 clinical trials, we observed similar rates of PASI 75/90 responses and higher percentages of patients achieving PASI 100. Patients who had not responded to previous biologic treatments and patients with cardio-metabolic comorbidities were significantly more likely to achieve PASI 100 at Week 28 and PASI 90 at Week 52. The higher body mass index did not interfere with the odds of reaching PASI 75/90/100 at each time point. No significant safety findings were recorded throughout the study, and none of the patients had to interrupt the treatment because of adverse events.</p> <p><strong>Conclusion: </strong> Our data suggest that the efficacy of tildrakizumab for plaque psoriasis in &#39;real-life&#39; clinical practice is comparable with Phase 3 clinical trials with higher percentages of patients achieving complete skin clearance (PASI 100) at Weeks 16, 28 and 52.</p>

restrictedNov 2022View details →
zenodo12/100

A THREE-DIMENSIONAL (3D) COMPARATIVE ASSESSMENT OF THE DENTOSKELETAL EFFECTS OF CLEAR ALIGNERS VERSUS TEMPORARY ANCHORAGE DEVICE (TAD)-ASSISTED POSTERIOR INTRUSION IN ADOLESCENTS WITH ANTERIOR OPEN BITE. A SINGLE-CENTER, RETROSPECTIVE, COHORT STUDY.

<p>Anterior Open Bite (AOB) is a malocclusion characterised by the absence of overbite and contact between upper and lower incisors in centric occlusion. AOB prevalence worldwide has been reported to be approximately 5-6%, with a higher occurrence in certain ethnic groups. Management of AOB malocclusion in growing patients varies and the armamentarium of conventional clinical practice includes habit cessation devices such as tongue crib and spurs, activators, and removable or fixed posterior bite blocks aimed at controlling tongue posture and posterior eruption respectively.&nbsp;Alternative methods for the correction of AOB include intrusion of posterior teeth using skeletal anchorage through temporary anchorage devices (TADs) and clear aligner therapy (CAT).&nbsp;The current literature indicates that TAD assisted molar intrusion induces open bite closure through mandibular counter-clockwise rotation of up to 3.9<sup> </sup>degrees.&nbsp;It has been suggested that clear aligners produce changes in the vertical dimension through a bite-block effect, facilitating counter-clockwise autorotation of the mandible and improving skeletal open bite. A recent study on adult patients concluded that reductions in AOB with CAT are largely a result of 1mm maxillary and mandibular incisor extrusion with some increases also noted in their lingual inclination, particularly in the maxilla.&nbsp;Most studies to date rely on two-dimensional (2D) cephalometric analyses of AOB treatment in both non-growing and adult patients.&nbsp;The aim of the present study was to compare the skeletal and dentoalveolar effects of CAT versus TAD-assisted intrusion of maxillary posterior teeth in growing adolescents with AOB using three-dimensional (3D) imaging. The null hypothesis assumed that there were no statistically significant differences in skeletal and dentoalveolar changes between the two groups. Additionally, the occlusion of the CAT group was assessed with the American Board of Orthodontists Objective Grading System (ABO-OGS) in order to provide evidence of the quality of final occlusion achieved with CAT.</p>

restrictedNov 2022View details →
zenodo12/100

Effectiveness and safety of epilepsy surgery for pediatric patients with intractable epilepsy: A clinical retrospective study from a single-center experience

<p><strong>In this single-centered study, pediatric patients were investigated retrospectivelty according to their ages (&gt;3 years old and &lt;3 years old) in order to demonstrate the efficacy and safety of surgical intervention.&nbsp;</strong></p>

restrictedJan 2023View details →
zenodo12/100

Prognostic relevance of quantitative and longitudinal MOG antibody testing in patients with MOGAD: a multicentre retrospective study

<p><strong>Introduction. </strong>The database contains information regarding patients with myelin oligodendrocyte glycoprotein associated disorders (MOGAD), including demographic, clinical presentation and course, neuroradiological data, laboratory data, treatment and outcome data and data regarding antibody titres over time.</p> <p><strong>Methods. </strong>In this retrospective multicentre Italian cohort study, we recruited patients with MOGAD and available longitudinal samples (at least one &gt;3 months after disease onset) and tested them with a live cell-based assay with endpoint titration (1:160 cut-off). Samples were classified as &rsquo;attack&rsquo; (within 30 days since a disease attack (n=59, 17%)) and &rsquo;remission&rsquo; (&ge;31 days after attack (n=295, 83%)).</p> <p><strong>Results . </strong>We included 102 patients with MOGAD (57% adult and 43% paediatric) with a total of 354 samples (83% from remission and 17% from attack). Median titres were higher during attacks (1:1280 vs 1:640, p=0.001). Median onset titres did not correlate with attack-related disability, age or relapses. Remission titres were higher in relapsing patients (p=0.02). When considering the first remission sample available for each patient, titres &gt;1:2560 were predictors of relapsing course in survival (log rank, p&lt;0.001) and multivariate analysis (p&lt;0.001, HR: 10.9, 95% CI 3.4 to 35.2). MOG-IgG seroconversion to negative was associated with a 95% relapse incidence rate reduction (incidence rate ratio: 0.05, p&lt;0.001). Persistent MOG-IgG positivity and high remission titres are associated with an increased relapse risk. Longitudinal MOG-IgG titres could be useful to stratify patients to be treated with long term immunosuppression.</p>

restrictedJun 2022View details →
zenodo12/100

Dataset related to article "Multimodal Treatments for Brain Metastases from Renal Cell Carcinoma: Results of a Multicentric Retrospective Study "

<p>This record contains raw data related to article "Multimodal Treatments for Brain Metastases from Renal Cell Carcinoma: Results of a Multicentric Retrospective Study"</p><p>Abstract</p><p>The aim of this study was to evaluate the clinical outcomes of a large series of brain metastatic renal cell carcinoma (BMRCC) patients treated in three Italian centers.</p><p><strong>Methods: </strong>A total of 120 BMRCC patients with a total of 176 lesions treated were evaluated. Patients received surgery plus postoperative HSRS, single-fraction SRS, or hypofractionated SRS (HSRS). Local control (LC), brain distant failure (BDF), overall survival (OS), toxicities, and prognostic factors were assessed.</p><p><strong>Results: </strong>The median follow-up time was 77 months (range 16-235 months). Surgery plus HSRS was performed in 23 (19.2%) cases, along with SRS in 82 (68.3%) and HSRS in 15 (12.5%). Seventy-seven (64.2%) patients received systemic therapy. The main total dose and fractionation used were 20-24 Gy in single fraction or 32-30 Gy in 4-5 daily fractions. Median LC time and 6 month and 1, 2 and 3 year LC rates were nr, 100%, 95.7% ± 1.8%, 93.4% ± 2.4%, and 93.4% ± 2.4%. Median BDF time and 6 month and 1, 2 and 3 year BDF rates were n.r., 11.9% ± 3.1%, 25.1% ± 4.5%, 38.7% ± 5.5%, and 44.4% ± 6.3%, respectively. Median OS time and 6 month and 1, 2 and 3 year OS rates were 16 months (95% CI: 12-22), 80% ± 3.6%, 58.3% ± 4.5%, 30.9% ± 4.3%, and 16.9% ± 3.6, respectively. No severe neurological toxicities occurred. Patients with a favorable/intermediate IMDC score, a higher RCC-GPA score, an early occurrence of BMs from primary diagnosis, absence of EC metastases, and a combined local treatment (surgery plus adjuvant HSRS) had a better outcome.</p><p><strong>Conclusions: </strong>SRS/HSRS is proven to be an effective local treatment for BMRCC. A careful evaluation of prognostic factors is a valid step to manage the optimal therapeutic strategy for BMRCC patients.</p>

restrictedOct 2023View details →
zenodo8/100

Occlusal outcome of orthodontic treatment with pre-adjusted straight-wire and standard Edgewise appliances: a retrospective cohort study

<p>Dataset for all analyses</p>

restrictedFeb 2020View details →
zenodo8/100

Severe acquired brain injury aetiologies, early clinical factors, and rehabilitation outcomes: a retrospective study on pediatric patients in rehabilitation.

<p>Raw data. Contains clinical and demographic data of 500+ pediatric patients in rehabilitation, analyzed in the article.</p>

restrictedAug 2019View details →
zenodo8/100

Long-term stability of orthodontically treated patients with a deep curve of Spee: a retrospective longitudinal study

<p>Dataset for all analyses. Initially, the dataset will be made available to the editor and reviewers for the peer-review phase. After acceptance, the dataset will be made openly available to anyone.</p>

restrictedApr 2023View details →
zenodo8/100

Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study

<p>Risankizumab is a humanized monoclonal antibody that binds the p19 subunit of interleukin-23. It is approved for treatment of moderate-severe chronic plaque psoriasis. This retrospective study included 66 consecutive adults with moderate-to-severe psoriasis vulgaris treated with risankizumab in monotherapy up to week 40 in a &ldquo;real-life&rdquo; setting. At week 40, 98.7%, 85.7% and 62.3% of patients achieved a Psoriasis Area and Severity Index (PASI) reduction &ge;75% (PASI 75), PASI 90 and PASI 100, respectively. Patients who had not responded to 2 or more previous biologic treatments were significantly less likely to achieve PASI 75/90 at week 16 and PASI 90/100 at week 40 compared with those who had been previously treated with only 1 biologic, and compared with those treated with risankizumab as a first-line biologic. Increasing body mass index decreased the chances of reaching PASI 90 at week 40. No significant safety findings were recorded throughout the study, and none of the patients had to interrupt the treatment. These data suggest that the efficacy of risankizumab for plaque psoriasis in &ldquo;real-life&rdquo; clinical practice could differ from pivotal clinical trials data.</p>

restrictedSep 2021View details →
zenodo8/100

The effect of leveling the curve of Spee on the inclination of lower incisors: a retrospective cephalometric study

<p>Datasets for all analyses</p>

restrictedDec 2021View details →
zenodo8/100

Predictors of orthodontic treatment duration: a retrospective study based on multisource data

<p>&nbsp;This study used logistic regression to analyze a multitude of samples and variables to identify the factors influencing the orthodontic treatment duration.</p>

restrictedSep 2022View details →
zenodo8/100

Short-term benefits of ventilotherapy on cognition in the obstructive sleep apnea syndrome: a retrospective study.

<p>This is the dataset associated to the paper: &quot;Short-term benefits of ventilotherapy on cognition in the obstructive sleep apnea syndrome: a retrospective study.&quot;</p>

restrictedNov 2022View details →
zenodo8/100

A + T ± status across MCI and dementia due to AD: a clinic‑based, retrospective study

<p>Dataset associated with the paper: &quot;A + T &plusmn; status across MCI and dementia due to AD: a clinic‑based,<br> retrospective study&quot;.</p>

restrictedJan 2023View details →
zenodo8/100

Dataset for the article "Cerebrospinal fluid/serum albumin quotient (Q-Alb) is not increased in Alzheimer's disease compared to neurological disease controls: a retrospective study on 276 patients"

<p>This is the anonymized dataset for the article entitled &quot;Cerebrospinal fluid/serum albumin quotient (Q-Alb) is not increased in Alzheimer&#39;s disease compared to neurological disease controls: a retrospective study on 276 patients&quot;.</p>

restrictedJan 2023View details →
zenodo8/100

Dataset for Verde et al., Neurol Sci 2023 - Relationship between cerebrospinal fluid/serum albumin quotient and phenotype in amyotrophic lateral sclerosis: a retrospective study on 328 patients

<p>This is the dataset for Verde et al., Neurol Sci 2023 - Relationship between cerebrospinal fluid/serum albumin quotient and phenotype in amyotrophic lateral sclerosis: a retrospective study on 328 patients.</p>

restrictedMar 2023View details →
zenodo8/100

Bulbar involvement and cognitive features in amyotrophic lateral sclerosis: a retrospective study on 347 patients.

<p>Dataset associated with the paper: &quot;Bulbar involvement and cognitive features in amyotrophic lateral sclerosis: a retrospective study on 347 patients.&quot;</p>

restrictedJun 2023View details →
zenodo4/100

Clinical implementation of third order angulation of incisors in the course of routine fixed appliance treatment - a retrospective cohort study

<p>Dataset for all analyses done in the paper.</p>

restrictedJul 2020View details →
zenodo4/100

The effect of four premolar extractions on the vertical dimension of the face: a retrospective cephalometric study

<p>Dataset for all analyses.</p>

restrictedDec 2021View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.